Sign In   |   Register
News: General

BioMed Alliance - Moving forward from drug-centred to patient-centred research

Monday 25 March 2019   (0 Comments)
Share |

EAS is one of the members of the Alliance for Biomedical Research in Europe (BioMed Alliance) and have approved the Code of Conduct of healthcare professionals and scientific organizations.

The BioMed Alliance Code of Conduct helps to ensure that EAS and the Alliance’s interactions and collaborations with the healthcare sector are for the benefit of patients and for the improvement of scientific standards and medical care.

The European Respiratory Journal published a white paper entitled "Moving forward from drug-centred to patient-centred research". It is based on a white paper on academic clinical research from 2018 that was initiated by EORTC and further developed by BioMed Alliance members. The updated version published in the European Respiratory Journal includes patient perspectives and policy angles to address issues related to academic clinical trials.

In order to bridge the existing gap between market approval and real-life clinical practice, a new infrastructure for applied clinical research is required. This infrastructure should be fully integrated into the cycle of drug development, market approval and clinical application. This process needs to be re-engineered in a such a way that it truly serves the needs of patients and generates the data needed to inform clinical practice.

To the white paper >>

Read more about EAS and the BioMed Alliance >>




Membership Software Powered by YourMembership  ::  Legal